Gadolinium-associated nephrogenic systemic fibrosis: The need for nephrologists' awareness

Journal of Nephrology

Volumn 21, Issue 3, 2008, Pages 324-336

  Canavese, Caterina ^a   Mereu, M Cristina ^b   Aime, Silvio ^c   Lazzarich, Elisa ^a   Fenoglio, Roberta ^a   Quaglia, Marco ^a   Stratta, Piero ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b BROTZU HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Contrast agent toxicity; Fibrillogenesis; Gadolinium; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECHOVIST; ERYTHROPOIETIN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IRON; PHOSPHATE; ZINC ION; CONTRAST MEDIUM;

ACIDOSIS; CLINICAL FEATURE; DISEASE SURVEILLANCE; GEOGRAPHIC DISTRIBUTION; HEMODIALYSIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; INCIDENCE; IRON OVERLOAD; KIDNEY DYSFUNCTION; METALLATION; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK ASSESSMENT; RISK FACTOR; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; FIBROSIS; METABOLISM; RENAL REPLACEMENT THERAPY; SKIN DISEASE;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; RENAL DIALYSIS; RISK FACTORS; SKIN DISEASES;

EID: 52049094408     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet. 2000;356:1000-1001.
2. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;39:903-906.
3. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
4. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
5. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. Am Acad Dermatol. 2007;56:710-712.
6. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586-592.
7. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27-30.
8. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157.
9. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174-3178.
10. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease. J Am Acad Dermatol. 2003;48:55-60.
11. Hubbard V, Davenport A, Jarmulowicz M, Rustin M. Scleromyxoedema-like change in four renal dialysis patients. Br J Dermatol. 2003;148:563-568.
12. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic Fibrosing Dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563-572.
13. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003;25:204-209.
14. Hauser C, Kaya G, Chizzolini C. Nephrogenic fibrosing dermopathy in a renal transplant recipient with tubulointerstitial nephritis and uveitis. Dermatology. 2004;209:50-52.
15. Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel disabling disorder in patients with renal failure. Nephrol Dial Transplant. 2004;19:469-473.
16. Lauchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004;208:278-280.
17. Gremmels JM, Kirk GA. Two patients with abnormal skeletal muscle uptake of Tc-99m hydroxymethylene diphosphonate following liver transplant: nephrogenic fibrosing dermopathy and graft vs host disease. Clin Nucl Med. 2004;29:694-697.
18. Chiu H, Wells G, Carag H, Canova E, Firpi RJ. Nephrogenic fibrosing dermopathy: A rare entity in patients awaiting liver transplantation. Liver Transpl. 2004;10:465-466.
19. Schmook T, Budde K, Ulrich C, Neumayer HH, Fritsche L, Stockfleth E. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant. 2005;20:220-222.
20. Dundova I, Treska V, Simanek V, Michal M. Nephrogenic fibrosing dermopathy: a case study. Transplant Proc. 2005;37:4187-4190.
21. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152:531-536.
22. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve. 2004;30:569-577.
23. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis. 2005;46:754-759.
24. Jan F, Segal JM, Dyer J, Leboit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr. 2003;143:678-681.
25. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003;139:928-930.
26. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;25:358.
27. Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol. 2004;150:1050-1052.
28. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36:598-606.
29. Frid MG, Brunetti JA, Burke DL, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol. 2006;168:659-669.
30. U.S. Food and Drug Administration (FDA). Public Health Advisory: Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Rockville, MD: U.S. Food and Drug Administration; June 2006. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed April 28, 2008.
31. U.S. Food and Drug Administration (FDA). Public Health Advisory: Update on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing Dermopathy. Rockville, MD: U.S. Food and Drug Administration; December, 2006. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm. Accessed April 28, 2008.
32. European Agency for the Evaluation of Medicinal Products (EMEA). Gadolinium-Containing MRI Contrast Agent and Nephrogenic Systemic Fibrosis. European Agency for the Evaluation of Medicinal Products; February, 2007. Available at: http://www.ismrm.org/special/EMEA1.pdf, http://www.ismrm.org/special/EMEA2.pdf, http://www.ismrm.org/special/ EMEA3.pdf. Accessed April 28, 2008.
33. U.S. Food and Drug Administration (FDA). Public Health Advisory: Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Rockville, MD: U.S. Food and Drug Administration; February, 2007. Available at: http://www.fda.gov/cder/drug/infopage/gcca/default.htm. Accessed April 28, 2008.
34. U.S. Food and Drug Administration. (FDA). Public Health Advisory: Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Rockville, MD: U.S. Food and Drug Administration; May, 2007. Available at: http://www.fda.gov/cder/drug/infopage/gcca/default.htm. Accessed April 28, 2008.
35. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acta Radiol. 1998;5:491-502.
36. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med. 2006;24:445-451.
37. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol. 2004;39:138-142.
38. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) versus Gd (HP-DO3A) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006;41:272-278.
39. Evans CH, Drouven BJ. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J. 1983;213:751-758.
40. Scott TL. Luminescence studies of Tb3+ bound to the high affinity sites of the Ca2+-ATPase of sarcoplasmic reticulum. J Biol Chem. 1984;259:4035-4037.
41. Drouven BJ, Evans CH. Collagen fibrillogenesis in the presence of lanthanides. J Biol Chem. 1986;261:11792-11797.
42. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol. 2007;2:200-202.
43. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol. 2001;42:339-341.
44. Chong HS, Garmestani K, Bryant LH Jr, et al. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging. J Med Chem. 2006;49:2055-2062.
45. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging. 2000;12:205-213.
46. Puttagunta NR, Gibby WA, Puttagunta VL. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest Radiol. 1996;31:619-624.
47. Idee J, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576.
48. Ueda J, Furukawa T, Higashino K, et al. Permeability of iodinated and MR contrast media through two types of hemodialysis membrane. Eur J Radiol. 1999;31:76-80.
49. Kimura J, Ishiguchi T, Matsuda J, et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med. 2005;23:322-326.
50. Corot C, Idee JM, Hentsch AM, et al. Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. J Magn Reson Imaging. 1998;8:695-702.
51. Vorobiov M, Basok A, Tovbin D, Shnaider A, Katchko L, Rogachev B. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol Dial Transplant. 2003;18:884-887.
52. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology. 2003;227:639-646.
53. Doorenbos CJ, Ozyilmaz A, van Wijnen M. Severe pseudohypocalcemia after gadolinium-enhanced magnetic resonance angiography. N Engl J Med. 2003;349:817-818.
54. Lin J, Idee JM, Port M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J Pharm Biomed Anal. 1999;21:931-943.
55. Normann PT, Froysa A, Svaland M. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest. 1995;55:421-426.
56. Lowe A, Balzer T, Hirt U. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. Invest Radiol. 2005;40:521-525.
57. Choyke PL, Knopp MV. Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale. Radiology. 2003;227:627-628.
58. Hershko K, Hull C, Ettefagh L, et al. A variant of nephrogenic fibrosing dermopathy with osteoclast-like giant cells: a syndrome of dysregulated matrix remodelling? J Cutan Pathol. 2004;31:262-265.
59. Jain SM, Wesson S, Hassanein A, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol. 2004;19:467-470.
60. Kanal E, Barkovich AJ, Bell C, et al. ACR Guidance Document for Safe MR Practices: 2007. American College of Radiology (ACR). Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/MRSafety/ safe_mr07.aspx. Accessed April 28, 2008.
61. Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol. 2004;140:1401-1405.
62. European Society Urogenital Radiology. Public Assessment Report: Increased Risk of Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis and Gadolinium-Containing MRI Contrast Agents. Available at: http://www.esur.org/fileadmin/Files/Public_Assessment_Report_NS_ gadolinium.pdf. Accessed April 28, 2008.
63. Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2006. The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR). http://www.icnfdr.org/. Accessed December 26, 2006.